Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Abbott has secured a European approval for the newest generation of its FreeStyle Libre continuous glucose monitor—which the company describes as the world’s smallest and thinnest diabetes sensor, ...

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

Freestyle-Libre-14-day_MPR-Image The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...